🇺🇸 FDA
Pipeline program

GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial

SP-GL0034-02

Phase 2 small_molecule active

Quick answer

GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial for Type 2 diabetes mellitus is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Type 2 diabetes mellitus
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials